title: Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation.
authors.affiliation: Department of Cardiology, Korea University Anam Hospital, Seoul, Korea.
authors.forename: Soon Jun
authors.initials: SJ
authors.lastname: Hong
authors.forename: Sung Tae
authors.initials: ST
authors.lastname: Kim
authors.forename: Tae-Jin
authors.initials: TJ
authors.lastname: Kim
authors.forename: Eun-Ok
authors.initials: EO
authors.lastname: Kim
authors.forename: Chul-Min
authors.initials: CM
authors.lastname: Ahn
authors.forename: Jae Hyoung
authors.initials: JH
authors.lastname: Park
authors.forename: Je Sang
authors.initials: JS
authors.lastname: Kim
authors.forename: Kyung-Mi
authors.initials: KM
authors.lastname: Lee
authors.forename: Do-Sun
authors.initials: DS
authors.lastname: Lim
mesh_terms: D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000097:blood; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000276:immunology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D054855:Drug-Eluting Stents; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006965:Hyperplasia; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000097:blood; D007328:Insulin / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000473:pathology; D000077205:Pioglitazone; D011446:Prospective Studies; D011474:Prosthesis Design; D054390:Receptors, CCR2 / Q000097:blood; D056910:Republic of Korea; D016037:Single-Blind Method; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D045162:Thiazolidinediones / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D017539:Tunica Intima / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000276:immunology; D018084:Ultrasonography, Interventional
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D002317:Cardiovascular Agents; D018932:Chemokine CCL2; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D018836:Inflammation Mediators; D007328:Insulin; D015850:Interleukin-6; D008055:Lipids; D000077205:Pioglitazone; D054390:Receptors, CCR2; D020123:Sirolimus; D045162:Thiazolidinediones; C111835:CCL2 protein, human; C515334:CCR2 protein, human; C508600:IL6 protein, human; C517652:hemoglobin A1c protein, human; C489443:zotarolimus